A recent study investigated the correlation between circulating B cells and clinical response as well as adverse effects in 39 patients with advanced melanoma receiving anti-PD-1 or anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) therapy alone, or in combination (10). The gene discussed is CTLA4; the disease is melanoma.